{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:01:31Z","timestamp":1648990891259},"reference-count":0,"publisher":"Polskie Towarzystwo Biochemiczne (Polish Biochemical Society)","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Postepy Biochem"],"abstract":"<jats:p>Celem artyku\u0142u jest synteza wiadomo\u015bci dotycz\u0105cych lek\u00f3w z grupy inhibitor\u00f3w monoaminooksydazy (IMAO) stosowanych w terapii depresji o r\u00f3\u017cnej etiologii. Przedstawiono og\u00f3lne wiadomo\u015bci dotycz\u0105ce czynno\u015bci oksydazy monoaminowej (MAO) i jej w\u0142a\u015bciwo\u015bci kinetyczne. Jest to enzym degraduj\u0105cy katecholaminy wraz z ich 3-metoksypochodnymi i inne monoaminy, takie jak serotonina i tryptamina. Om\u00f3wione zosta\u0142y osobno kryteria i objawy zaburze\u0144 depresyjnych. Nale\u017cy je rozr\u00f3\u017cnia\u0107 ze stanami smutku i podobnymi. Podstawowe objawy dotycz\u0105 g\u0142osu, mimiki, anhedonii i spowolnienia psychoruchowego. Mog\u0105 si\u0119 one r\u00f3\u017cni\u0107 w poszczeg\u00f3lnych podjednostkach klinicznych. Wskazany zosta\u0142 podstawowy mechanizm dzia\u0142ania IMAO: hamuj\u0105c MAO zmniejszaj\u0105 rozk\u0142ad monoamin, co skutkuje zwi\u0119kszeniem st\u0119\u017cenia neuroprzeka\u017anika w szczelinie synaptycznej. Kolejne podrozdzia\u0142y po\u015bwi\u0119cono przedstawieniu wiadomo\u015bci o wybranych IMAO-A selektywnych i odwracalnych. S\u0105 to obecnie najbezpieczniejsze i najskuteczniejsze leki z grupy IMAO, kt\u00f3re mo\u017cna stosowa\u0107 w leczeniu chor\u00f3b depresyjnych. Om\u00f3wiono: moklobemid, befloksaton, toloksaton oraz brofaromin\u0119. Wysuni\u0119to wnioski ko\u0144cowe i podsumowano przedstawione wiadomo\u015bci.\u00a0<\/jats:p>","DOI":"10.18388\/pb.2021_382","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T19:50:10Z","timestamp":1621972210000},"source":"Crossref","is-referenced-by-count":0,"title":["Inhibitory monoaminooksydazy (IMAO): farmakologia, metabolizm i zastosowanie w terapii depresji o r\u00f3\u017cnej etiologii"],"prefix":"10.18388","author":[{"given":"\u0141ukasz","family":"Grabowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7609","published-online":{"date-parts":[[2021,5,25]]},"container-title":["Post\u0119py Biochemii"],"original-title":[],"link":[{"URL":"https:\/\/postepybiochemii.ptbioch.edu.pl\/index.php\/PB\/article\/download\/382\/790","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/postepybiochemii.ptbioch.edu.pl\/index.php\/PB\/article\/download\/382\/791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/postepybiochemii.ptbioch.edu.pl\/index.php\/PB\/article\/download\/382\/790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T19:50:11Z","timestamp":1621972211000},"score":1,"resource":{"primary":{"URL":"https:\/\/postepybiochemii.ptbioch.edu.pl\/index.php\/PB\/article\/view\/382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":0,"URL":"https:\/\/doi.org\/10.18388\/pb.2021_382","relation":{},"ISSN":["0032-5422"],"issn-type":[{"value":"0032-5422","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}